Connect Biopharma says Phase 2 trial shows rademikibart cuts COPD treatment failure rate 81% through Week 4

By Public Technologies
  • Connect Biopharma reported positive preliminary topline results from a global Phase 2 trial of rademikibart in acute COPD flare-ups.
  • Results have been presented already, with a conference call scheduled for today at 8:00 a.m. ET.
  • The drug cut post-flare treatment failures versus placebo, with fewer repeat medical visits in the month following dosing.
  • It also lowered new moderate-to-severe flare-ups, with no return emergency visits or hospitalizations reported in the treatment arm.
  • The company plans to seek FDA alignment on a Phase 3 registrational program for rademikibart as an add-on COPD therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300700PRIMZONEFULLFEED9836501) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.